Psychopharmacology

A small pilot study found that a single 25 mg dose of psilocybin led to lasting reductions in depression symptoms among U.S. military veterans with treatment-resistant depression. Half were in remission after six months; 30% remained in remission at one...

Brain recordings suggest that ibogaine slows the brain’s dominant rhythms and reduces signal variability in veterans with traumatic brain injury—patterns that were associated with improved executive function, reduced PTSD symptoms, and lowered anxiety.

Adults with anxiety who used cannabis reacted more strongly to stress but also bounced back more effectively. The study, published in the Journal of Psychopathology and Clinical Science, examined real-world cannabis use and emotional processing.

New research has found that inattention symptoms predict functional cannabis-related harms like academic difficulties and memory blackouts, while hyperactivity symptoms are linked to heavier use and increased dependence, pointing to distinct risk pathways in young adults with ADHD.

A groundbreaking study has revealed that classical psychedelics affect far more than just serotonin. By mapping how 41 compounds interact with brain receptors, researchers challenge long-held assumptions and open new directions for psychedelic science and therapeutic development.

People diagnosed with cannabis use disorder tend to perform worse on memory and thinking tasks, according to new research. The study found moderate cognitive deficits, especially in learning and processing speed.

Cancer patients with major depression experienced significant and long-lasting improvements after just one psilocybin session, according to new research. Two years later, many showed continued reductions in depression and anxiety, with some requiring no further treatment or medication.

Psilocybin and MDMA may do more than alter perception. A study in Nature suggests they also reduce fear by targeting a newly identified immune-brain signaling loop, which becomes hyperactive under chronic stress and contributes to heightened fear responses.

A non-intoxicating cannabis compound may help protect the brain from the damaging effects of chronic social stress. New research shows cannabidiol reversed stress-related changes in behavior and gene expression in mice exposed to repeated social defeat.

A new study suggests the dopamine-boosting drug tolcapone may enhance self-control and reduce alcohol intake in people with alcohol use disorder by increasing activity in brain regions linked to inhibitory control, such as the inferior frontal gyrus and prefrontal cortex.

A new study suggests that children exposed to cannabis in utero show reduced brain activation during reward anticipation—especially in the striatum—and are more likely to report psychotic-like experiences during adolescence. The findings provide evidence of altered neural development tied to...

A new study challenges previous claims that antidepressant withdrawal is rare or mild. Researchers found that more than half of patients report symptoms when discontinuing, suggesting earlier reviews relying on short-term trials may have underestimated the risks.

A recent case report describes how a 67-year-old man was misdiagnosed with schizophrenia after experiencing hallucinations—an adverse reaction linked to his prescribed opioid pain medication. The case highlights the need for more nuanced psychiatric evaluations.

A new study comparing near-death experiences with high-dose DMT trips finds striking similarities — and surprising differences — in what people see and feel. The research sheds light on how the brain might shape extraordinary states of consciousness.

A new clinical trial suggests that esketamine nasal spray, used alone without oral antidepressants, may reduce depressive symptoms in patients with treatment-resistant depression. The fast-acting treatment showed benefits within 24 hours and sustained effects over four weeks.